8-K: agilon health Faces NYSE Delisting, Plans Reverse Stock Split

agilon health received a notice from the NYSE for non-compliance with its minimum share price requirement and plans a reverse stock split to regain compliance.

Summary

• agilon health, inc. received a written notice from the New York Stock Exchange (NYSE) on November 5, 2025, indicating non-compliance with Section 802.01C of the NYSE Listed Company Manual.
• The non-compliance is due to the company's common stock having an average closing price of less than $1.00 per share over a consecutive 30 trading-day period, which ended on November 4, 2025.
• The company has a six-month cure period to regain compliance, which requires a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the prior 30 trading days.
• agilon health intends to notify the NYSE by November 19, 2025, of its plan to remain listed.
• To regain compliance, the company anticipates pursuing a reverse stock split, subject to stockholder approval at its annual general meeting in 2026.
• The notice has no immediate impact on the listing or trading of the company's common stock, nor on its ongoing business operations or SEC reporting requirements.

Sentiment

Score: 3

Explanation: The receipt of a delisting notice due to a low stock price is a significant negative event, reflecting poor market perception and potential underlying business challenges. While the company has a plan to address compliance, a reverse stock split is a cosmetic solution that does not resolve fundamental performance issues. The extensive list of risks further contributes to a negative sentiment.

Positives

• The company has a defined six-month cure period to regain compliance with NYSE listing standards.
• The company has a clear plan to address the non-compliance by pursuing a reverse stock split, subject to stockholder approval.
• The notice does not immediately impact the listing or trading of the company's common stock, allowing time to implement the compliance plan.
• Ongoing business operations and SEC reporting requirements are not anticipated to be impacted by the notice.

Negatives

• The company's common stock failed to maintain an average closing price of $1.00 over a 30-trading-day period, leading to NYSE non-compliance.
• A reverse stock split, while a mechanism to regain compliance, does not address the underlying business performance issues that led to the low stock price.
• Stockholder approval for a reverse stock split is required, introducing a potential point of failure for the compliance plan.

Risks

• Inability to regain compliance with NYSE's continued listing standards, including by completing a reverse stock split.
• History of net losses and expectation that expenses will increase in the future.
• Failure to identify and develop successful new geographies, physician partners, and payors, or execute upon growth initiatives.
• Inability to execute operating strategies or achieve results consistent with historical performance.
• Medical expenses incurred on behalf of members may exceed revenues received.
• Inability to maintain and secure additional contracts with Medicare Advantage payors on favorable terms.
• Inability to grow new physician partner relationships sufficient to recover startup costs.
• Availability of additional capital, on acceptable terms or at all, to support the business in the future.
• Significant reduction in membership.
• Challenges for physician partners in transitioning to a Total Care Model.
• Public health crises, such as pandemics or epidemics, could adversely affect the company.
• Inaccuracy in estimates of members' risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts.
• Impact of restrictive clauses or exclusivity provisions in some contracts with physician partners.
• Inability to hire and retain qualified personnel.
• Inability to realize the full value of intangible assets.
• Security breaches, cybersecurity attacks, loss of data, and other disruptions to information systems.
• Inability to protect the confidentiality of know-how and other proprietary and internally developed information.
• Reliance on subsidiaries to perform and fund their operations.
• Challenges with properly managing the development and use of artificial intelligence and machine learning technologies.
• Reliance on a limited number of key payors.
• Limited terms of contracts with payors and inability to renew them upon expiration.
• Inability to navigate the changing healthcare payor market.
• Reliance on payors, physician partners, and other providers to operate the business.
• Inability to obtain accurate and complete diagnosis data.
• Reliance on third-party software, data, infrastructure, and bandwidth.
• Consolidation and competition in the healthcare industry.
• Impact of changes to, and dependence on, federal government healthcare programs.
• Uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures.
• Regulation of the healthcare industry and the company's and its physician partners' ability to comply with such laws and regulations.
• Federal and state investigations, audits, and enforcement actions.
• Repayment obligations arising out of payor audits.
• Negative publicity regarding the managed healthcare industry generally.
• Use, disclosure, and processing of personally identifiable information, protected health information, and de-identified data.
• Failure to obtain or maintain an insurance license, a certificate of authority, or an equivalent authorization.
• Changes in tax laws and regulations, or changes in related judgments or assumptions.
• Indebtedness and potential to incur more debt.
• Dependence on subsidiaries for cash to fund all operations and expenses.
• Provisions in governing documents.
• Ability to achieve a return on investment depends on appreciation in the price of common stock.
• Lawsuits not covered by insurance and securities class action litigation.
• Sustainability issues.
• Stock price may be volatile.
• Risks related to management transitions, including the search for a permanent CEO, and ability to effectively manage leadership changes.
• Ongoing implementation of performance initiatives, leadership changes, and dynamic market conditions create additional uncertainty regarding future operating and financial performance.

Future Outlook

The company plans to regain compliance with NYSE listing standards within the six-month cure period by pursuing a reverse stock split, subject to stockholder approval at its 2026 annual general meeting. If approved and implemented, the share price must promptly exceed $1.00 and remain above that level for at least 30 trading days.

Management Comments

• agilon health, inc. announced that the New York Stock Exchange issued a notice informing the company of non-compliance with its continued listing standards.

Industry Context

agilon health operates in the healthcare sector, specifically focusing on empowering physicians to transition to a value-based Total Care Model for senior patients, particularly within Medicare Advantage. This announcement primarily concerns a company-specific stock market compliance issue rather than broader industry trends, although general economic conditions and healthcare regulatory changes are noted as potential risks to its business model.

Comparison to Industry Standards

• The company's stock price performance fell below the New York Stock Exchange's specific Price Criteria for Capital or Common Stock, which mandates an average closing price of at least $1.00 over a 30-trading-day period. This is a standard compliance requirement for all listed companies, and failure to meet it indicates significant underperformance relative to this benchmark.

Corporate Governance

Legal Proceedings

• The company lists 'lawsuits not covered by insurance and securities class action litigation' as a general risk factor, but no specific current legal proceedings are detailed in this filing.

Stakeholder Impact

• Shareholders: Face potential delisting risk, uncertainty regarding the effectiveness of a reverse stock split, and the need to approve the proposed action. A reverse stock split changes the number of shares outstanding but not the total value of their holdings, though it can be perceived negatively.
• Employees: No direct impact mentioned, but the company's financial health and listing status can indirectly affect employee morale and long-term stability.
• Customers/Physician Partners: No immediate direct impact on service delivery or partnerships, but concerns about the company's financial stability could arise.
• Creditors: No direct impact mentioned, but a delisting could potentially trigger certain covenants or affect the company's ability to raise future debt.

Next Steps

• Notify the NYSE by November 19, 2025, of the intent to remain listed.
• Pursue a reverse stock split, which requires approval by the company's stockholders.
• Seek stockholder approval for the reverse stock split at the annual general meeting in 2026.
• If stockholder approval is obtained and the action is implemented, the share price must promptly exceed $1.00 per share and remain above that level for at least 30 trading days to cure the deficiency.

Key Dates

Recommendation

The company's receipt of a delisting notice from the NYSE due to its stock trading below the minimum price threshold is a severe negative indicator. While management proposes a reverse stock split to regain compliance, this is a cosmetic measure that does not address the fundamental business issues driving the low valuation. The extensive list of risks, including a history of net losses and challenges in growth, further underscores significant operational and financial headwinds. Investors should consider selling to mitigate exposure to a company facing delisting uncertainty and substantial underlying business challenges.

Keywords

agilon health, NYSE, delisting notice, stock price compliance, reverse stock split, AGL, healthcare, value-based care, Medicare Advantage, corporate governance